Twin Capital Management Inc. Cuts Position in Hologic, Inc. $HOLX

Twin Capital Management Inc. decreased its position in Hologic, Inc. (NASDAQ:HOLX) by 77.5% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 5,337 shares of the medical equipment provider’s stock after selling 18,345 shares during the quarter. Twin Capital Management Inc.’s holdings in Hologic were worth $360,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Winnow Wealth LLC acquired a new stake in shares of Hologic in the 3rd quarter valued at $26,000. Root Financial Partners LLC purchased a new position in Hologic in the third quarter valued at $27,000. Caitong International Asset Management Co. Ltd raised its stake in Hologic by 193.6% in the second quarter. Caitong International Asset Management Co. Ltd now owns 414 shares of the medical equipment provider’s stock valued at $27,000 after buying an additional 273 shares in the last quarter. SJS Investment Consulting Inc. raised its stake in Hologic by 341.5% in the third quarter. SJS Investment Consulting Inc. now owns 468 shares of the medical equipment provider’s stock valued at $32,000 after buying an additional 362 shares in the last quarter. Finally, Loomis Sayles & Co. L P purchased a new stake in Hologic during the 2nd quarter worth about $33,000. Institutional investors and hedge funds own 94.73% of the company’s stock.

Hologic Price Performance

Hologic stock opened at $74.81 on Monday. The company has a debt-to-equity ratio of 0.48, a current ratio of 4.04 and a quick ratio of 3.32. The business has a 50 day simple moving average of $74.87 and a 200-day simple moving average of $71.31. Hologic, Inc. has a 12 month low of $51.90 and a 12 month high of $75.36. The stock has a market capitalization of $16.70 billion, a PE ratio of 31.17, a price-to-earnings-growth ratio of 2.23 and a beta of 0.72.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings data on Thursday, January 29th. The medical equipment provider reported $1.04 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.09 by ($0.05). Hologic had a net margin of 13.18% and a return on equity of 19.58%. The firm had revenue of $1.05 billion during the quarter, compared to analyst estimates of $1.07 billion. During the same period in the prior year, the firm posted $0.87 earnings per share. The business’s quarterly revenue was up 2.5% compared to the same quarter last year. Equities analysts predict that Hologic, Inc. will post 4.28 earnings per share for the current year.

Wall Street Analyst Weigh In

HOLX has been the topic of a number of recent analyst reports. Needham & Company LLC reiterated a “hold” rating on shares of Hologic in a report on Tuesday, November 4th. BTIG Research reiterated a “neutral” rating on shares of Hologic in a research note on Tuesday, October 21st. Mizuho cut shares of Hologic from an “outperform” rating to a “neutral” rating and raised their price objective for the stock from $70.00 to $78.00 in a report on Thursday, October 23rd. JPMorgan Chase & Co. restated a “neutral” rating and issued a $78.00 target price on shares of Hologic in a report on Wednesday, October 22nd. Finally, Evercore downgraded shares of Hologic from an “outperform” rating to an “in-line” rating and dropped their target price for the company from $79.00 to $78.00 in a research report on Monday, January 5th. Two analysts have rated the stock with a Buy rating and thirteen have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $78.42.

Hologic Profile

Hologic, Inc (NASDAQ: HOLX) is a global medical technology company specializing in women’s health. Headquartered in Marlborough, Massachusetts, the company develops and manufactures diagnostic products, imaging systems and surgical solutions designed to detect, diagnose and treat diseases with a primary focus on breast and skeletal health, gynecological conditions and molecular diagnostics. Its product portfolio includes digital mammography systems, 3D mammography solutions, bone densitometry equipment and molecular assays for infectious disease and oncology applications.

Since its founding in 1985, Hologic has grown through both internal innovation and strategic acquisitions.